{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:25:35Z","timestamp":1770989135564,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s13318-020-00651-3","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T11:03:06Z","timestamp":1605178986000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study"],"prefix":"10.1007","volume":"46","author":[{"given":"Thomas L.","family":"Hunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Tzanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Manley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"issue":"11","key":"651_CR1","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1128\/AAC.01536-15","volume":"59","author":"L Honeyman","year":"2015","unstructured":"Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59(11):7044\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement 1","key":"651_CR2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/ciz396","volume":"69","author":"FM Abrahamian","year":"2019","unstructured":"Abrahamian FM, Sakoulas G, Tzanis E, Manley A, Steenbergen J, Das AF, et al. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;69(Supplement 1):S23\u2013S32.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"651_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19(10):1080\u201390.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"651_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327.","journal-title":"N Engl J Med"},{"issue":"24","key":"651_CR5","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6409\u201319.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"651_CR6","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","volume":"60","author":"H Sun","year":"2016","unstructured":"Sun H, Ting L, Machineni S, Praestgaard J, Kuemmell A, Stein DS, et al. Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects. Antimicrob Agents Chemother. 2016;60(12):7431\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"651_CR7","doi-asserted-by":"crossref","unstructured":"Bundrant LA, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens. Antimicrob Agents Chemother. 2018;62(2):e01487-17.","DOI":"10.1128\/AAC.01487-17"},{"key":"651_CR8","doi-asserted-by":"crossref","unstructured":"Berg JK, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother. 2018;62(2):e02057-17.","DOI":"10.1128\/AAC.02057-17"},{"key":"651_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421\u201334.","journal-title":"Future Microbiol"},{"issue":"8","key":"651_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2017","unstructured":"Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica. 2017;47(8)682\u201396.","journal-title":"Xenobiotica"},{"key":"651_CR11","unstructured":"US Food and Drug Administration. Drug\u2013drug interactions. FDA draft guidance for industry. Silver Spring: US FDA; 2012."},{"issue":"8","key":"651_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2017","unstructured":"Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica. 2017;47(8):682\u201396.","journal-title":"Xenobiotica"},{"issue":"1","key":"651_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2165\/00003088-198409010-00002","volume":"9","author":"SR Hamann","year":"1984","unstructured":"Hamann SR, Blouin RA, McAllister RG Jr. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet. 1984;9(1):26\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"651_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF03189707","volume":"10","author":"J Mattila","year":"1985","unstructured":"Mattila J, M\u00e4ntyl\u00e4 R, Taskinen J, M\u00e4nnist\u00f6 P. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. Eur J Drug Metab Pharmacokinet. 1985;10(2):133\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"Supplement 1","key":"651_CR15","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69(Supplement 1):S16\u2013S22.","journal-title":"Clin Infect Dis"},{"issue":"115","key":"651_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejps.2018.01.043","volume":"30","author":"F Afonso-Pereira","year":"2018","unstructured":"Afonso-Pereira F, Dou L, Trenfield SJ, Madla CM, Murdan S, Sousa J, et al. Sex differences in the gastrointestinal tract of rats and the implications for oral drug delivery. Eur J Pharm Sci. 2018;30(115):339\u201344.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"651_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/dmd.104.002469","volume":"33","author":"MF Paine","year":"2005","unstructured":"Paine MF, Ludington SS, Chen ML, Stewart PW, Huang SM, Watkins PB. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos. 2005;33(3):426\u201333.","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-020-00651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T20:41:45Z","timestamp":1669581705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-020-00651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s13318-020-00651-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"12 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Paratek Pharmaceuticals, Inc., King of Prussia, PA. Medical writing and editorial assistance was provided by Theresa Singleton, PhD, and Linda Edmondson of Innovative Strategic Communications, LLC, which was funded by Paratek Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Open access publication of this manuscript was sponsored by Paratek Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open Access"}},{"value":"A.M. is an employee of Paratek Pharmaceuticals, Inc. P.C.M. is a former employee of, has received consulting fees from, and is a shareholder of Paratek Pharmaceuticals, Inc. E.T. is a former employee and current shareholder of Paratek Pharmaceuticals, Inc. S.B. is a consultant to Paratek Pharmaceuticals Inc. in matters relating to clinical pharmacology and\/or drug disposition, including pharmacokinetics, aspects in study design, and data interpretation. S.C. is a consultant to Paratek Pharmaceuticals Inc. T.L.H. has no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written and signed informed consent was obtained from each study participant before any protocol-specific assessment was performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable; patient level data are not included in this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not-applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board or independent ethics committee for each study center, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written and signed informed consent was obtained from each study participant before any protocol-specific assessment was performed. The study was described by investigators and written information was given to each participant.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"Paratek Pharmaceuticals has a commitment to ensure that access to clinical trial data is available to regulators, researchers, and trial participants, when permitted, feasible and appropriate. Requests for de-identified patient-level data may be submitted to medinfo@paratekpharma.com for review. Datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request. The Food and Drug Administration 2019 Advisory Committee report on omadacycline can be accessed here:.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}